Data Integrity Risk Detected for Alexion’s Approval-Pending Bleeding Antidote, Report to Panel Put on Hold

Alexion Pharmaceuticals’ andexanet alfa, an antidote for factor Xa inhibitors, was expected to be approved by the end of September, but a data integrity risk that has been detected is now casting clouds on this timeline. Andexanet alfa, known as...read more